V.N. TSIBULKINA¹, N.A. TSIBULKIN²

¹Kazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

²Kazan State Medical Academy, 36 Butlerov Str., Kazan, Russian Federation, 420012

 Tsibulkina V.N. ― D. Med. Sc., Head of the Department of Clinical Immunology and Allergology, tel. (843) 261-74-11, е-mail: kldkgma@mail.ru

Tsibulkin N.A. ― Cand. Med. Sc., Associate Professor of the Department of Cardiology, tel. (843) 261-74-11, e-mail: kldkgma@mail.ru

One of the important functional elements of immune system is the mast cell. The clinical value of mast cells is mainly defined by their role in the development of reactions of immediate hypersensitivity and anaphylaxis. At the same time, the immune mechanism of mast cell degranulation related to IgE is not the only one. A number of diseases contain in their pathogenesis the components determined by mast cells and their non-immune activation, one of which is mastocytosis. The excessive accumulation of mast cells in various body tissues that leads to development of local and systemic clinical symptoms is the cornerstone of this pathology. Diagnostics and assessment of the forecast at this disease are complicated by both the age differences of its course and multi-systemic lesions. The common pathogenetic mechanisms of mastocytosis and allergic diseases form a certain similarity of clinical symptoms of these diseases, which are different in essence. The key aspects of mast cells pathophysiology allow to disclose their role in mastocytosis clinical picture and define the main directions in its diagnostics.

Key words: mast cells, mastocytosis, pathogenesis, diagnosis.

REFERENCES

1. Metcalfe D., Mekori J., Rottem M. Mast cell ontogeny and apoptosis. Exp. Dermatol, 1995, 4 (4, Pt 2), pp. 227-30.
2. Wilson T., Maric I., Simakova O., et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica, 2011, 96 (3), pp. 459-63.
3. Castells M., Metcalfe D., Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am. J. Clin. Dermatol, 2011, 12 (4), pp. 259-70.
4. Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification and management. Am. J. Hematol, 2013, 88 (7), pp. 612-24.
5. Intzes S., Wiersma S., Meyerson H. Myelomastocytic leukemia with t(8;21) in a 3-year-old child. J. Pediatr. Hematol. Oncol, 2011, 33 (8), e372-75.
6. Pardanani A. Systemic mastocytosis: evolving lessons from large patient registry datasets. Am. J. Hematol, 2016, 91 (7), pp. 654-5.
7. Laroche M., Livideanu C., Paul C., et al. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am. J. Med, 2011, 124 (8), pp. 776-78.
8. Gadage V., Kadam Amare P., Galani K., et al. Systemic mastocytosis with associated acute myeloid leukemia with t(8;21) (q22;q22). Indian J. Pathol. Microbiol, 2012, 55 (3), pp. 409-12.
9. Sokol H., Georgin-Lavialle S., Canioni D., et al. Gastrointestinal manifestations in mastocytosis: a study of 83 patients. J. Allergy Clin. Immunol, 2013, 132 (4), pp. 866-73.e3.
10. Seo H., Park S., Byeon J. Chronic intractable diarrhea caused by gastrointestinal mastocytosis. Intest. Res, 2016, 14 (3), pp. 280-4.
11. Valent P., Aberer E., Beham-Schmid C., et al. Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). Am. J. Blood Res, 2013, 3 (2), pp. 174-180.
12. Rabade N., Tembhare P., Patkar N. Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia. Indian J. Pathol. Microbiol, 2016, 59 (3), pp. 407-9.
13. Morgado J., Sanchez-Munoz L., Teodosio C., et al. Immunophenotyping in systemic mastocytosis diagnosis: “CD25 positive” alone is more informative than the “CD25 and/or CD2” WHO criterion. Mod. Pathol, 2012, 25 (4), pp. 516-21.
14. Mahadeo K., Wolgast L., McMahon C., et al. Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia. Pediatr. Blood Cancer, 2011, 57 (4), pp. 684-87.
15. Ravichandran S., Chitrapur R.G., Bhave S. Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat. Indian J. Hematol. Blood Transfus, 2016, 32 (Suppl 1), pp. 108-11.
16. Gadage V., Kadam Amare P., Galani K., et al. Systemic mastocytosis with associated acute myeloid leukemia with t(8;21) (q22;q22). Indian J. Pathol. Microbiol, 2012, 55 (3), pp. 409-12.